Zobrazeno 1 - 4
of 4
pro vyhledávání: '"MIKKEL A. AGERSNAP"'
Publikováno v:
Clinical Pharmacokinetics. 62:645-651
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfd6089779123f5888fbba970e8365b2
https://doi.org/10.1007/s40262-023-01215-9
https://doi.org/10.1007/s40262-023-01215-9
Autor:
Mikkel Askjær Agersnap, Kim Sonne, Kim Mark Knudsen, Carsten Boye Knudsen, Mark Berner-Hansen
Publikováno v:
Clinical Drug Investigation. 42:1093-1100
Glepaglutide is a novel, long-acting, glucagon-like peptide-2 analogue in a stable aqueous formulation for subcutaneous dosing to treat patients with short bowel syndrome. This study was conducted primarily to characterise the pharmacokinetics of gle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d39176f5935f719fe795ad50ae93336
https://doi.org/10.1007/s40261-022-01210-1
https://doi.org/10.1007/s40261-022-01210-1
Publikováno v:
Clinical Pharmacokinetics. 62:653-654
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c3dfc367a638623efad652d0fc13279
https://doi.org/10.1007/s40262-023-01236-4
https://doi.org/10.1007/s40262-023-01236-4
Autor:
MINNA B. OLSEN, ULRIKE HÖVELMANN, JON GRIFFIN, KIM M. KNUDSEN, PER-OLOF ERIKSSON, MIKKEL A. AGERSNAP
Publikováno v:
Diabetes. 71
Dapiglutide is a first-in-class peptide with dual activity on the GLP-1 and GLP-2 receptors and with potential to treat several metabolic/gastrointestinal (GI) diseases. In a multiple ascending dose cohort trial, 40 healthy subjects (mean BMI 24.6 kg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c46bda5cf93a8951df83bda5423262dc
https://doi.org/10.2337/db22-335-or
https://doi.org/10.2337/db22-335-or